Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

Life Science Nation Scores A “Hat Trick” with the Third RESI in Toronto – April 10th at MaRS Discovery District

18 Jan

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

LSN is pleased to announce that RESI on MaRS is on schedule to land in Toronto April 10th, and JLABS and MaRS Discovery District will be the Title Sponsors. The big news here is that this event will be larger from an international perspective than previous RESI on MaRS events. The global early stage life science investor and partnering community has stepped up efforts to source technology assets throughout North America, and Toronto has a trove of up and coming startups across the domains of drugs, devices, diagnostics, and healthcare IT.

LSN has built a compelling group of investors and strategic partners (dubbed “the tribe”) that use the RESI conferences as a vehicle to source and vet new technologies. These investors all have a mandate to allocate capital resources in order to fill their portfolios and product pipelines and expand their global channels. LSN has already seen very strong interest from investors based in Asia, Europe and the U.S., who are vying for panel slots at the upcoming conference. RESI’s panels will feature investors from Asia-based pharma and strategics, global family offices, venture capital firms, angel syndicates, private equity, corporate venture, foundations and impact funds. The market is heating up for early stage technology, and 2018 looks like it will be a banner year for dynamic global partnerships.

Last year, RESI on MaRS hosted over 250 Canadian and international investors who participated over 900 meetings with fundraising CEOs and scientist-entrepreneurs in one day. These investors went to Toronto with mandates for investment and indeed fostered relationships that led to deals. Part of RESI on MaRS is the Innovation Challenge which will feature 30 top life science startups that has become a major draw for the investors that attend the event. The Innovation Challenge showcases these local startups on a global stage.

MaRS and JLABS will work together to showcase best-of-breed technology to the global players at this event. RESI is also part of the Toronto Health Innovation Week, which features a bevy of activity over the course of five days, leveraging the fact that RESI on MaRS will bring in the global players. Looking forward to seeing you on MaRS!

Also Offering Premier Partnering Plus

Tags: ,

RESI on MaRS 2017 Dynamic Statistics

18 Jan

By Chris Cummings, Senior Marketing Manager, LSN

In April 2017, RESI brought over 250 qualified life science investors to the Toronto ecosystem. The investors came from all corners of the globe; large strategic partners flew in from China to join local family offices just down the street from MaRS Discovery District. Over 900 meetings occurred over the course of the day. Taking a closer look at exactly where investors came from and who they met with confirms the global cross-pollination of early stage life science RESI fosters.

RESI, for that day, was able to expand the pool of capital in Toronto beyond Canada’s borders. About 50% of the investors who attended the event were from the United States, Europe, or Asia.

Investment firm types were far from homogenous as well. No single category of investor dominated the event, creating a platform where every fundraising company can find the capital that most accurately suits their needs.

Investors came to RESI on MaRS primarily to meet with new interesting technology. Over 80% of investor meetings were with fundraising companies.

RESI also offers a platform for fundraising companies to collaborate with relevant service providers, non-profits, and even other fundraising companies.

This data goes to show that RESI on MaRS truly offers an unparalleled platform for players in the early stage life science game to find partners from across the world, driving innovation forward and, ultimately, putting much needed treatments in the hands of patients.

Tags: , ,

Toronto Health Innovation Week – 2018

18 Jan

By Gregory Mannix, Vice President International Business Development, LSN

Where Health Means Business
For the second year running, RESI on MaRS will be the centerpiece event of the Toronto Health Innovation Week, taking place from April 9th to 13th, 2018. 30+ events will be taking place that week in the Toronto Region, bringing together key players in the life sciences from Canada and around the globe. Life science entrepreneurs, investors, opinion leaders and many others will converge on the region for an intense week of partnering and discussions. Here are some of the highlights:

Impact Health Summit. April 9th (All day)
Industry leaders and stakeholders from Canada and the world come together to build new partnerships and accelerate the ecosystem. The day will include keynotes and panels from industry leaders, roundtables, workshops and the Health Partnering Forum.

HealthKick Investor Summit. April 9th (Afternoon)
An inside look at the emerging trends, opportunities and challenges shaping the investment climate for human health and life sciences. Gain insight into the state of financing in healthcare today and the industry developments driving investments.

RESI on MaRS. April 10th (All day)
350+ global investors and strategics will meet 350+ early-stage life science companies and quality service providers in the industry’s premier partnering event for funding.

Also Offering Premier Partnering Plus

For more information: https://www.healthinnovationweek.ca/

Are You Ready For RESI JPM? Time To Check Out The Program Guide

4 Jan

By Nono Hu, Director of Marketing, LSN

JPM week is almost upon us, and at Life Science Nation, we’re making the final preparations for RESI San Francisco. It’s our largest event of the year; if you want to join over a thousand life science executives and investors for targeted one-on-one meetings, you’ve got 5 more days to sign up. In the meantime, please check out the RESI Program Guide below to see all our RESI Innovators, sponsors, exhibitors and speakers. With attendees from all over the world coming to RESI to make new connections and continue compelling dialogues, RESI San Francisco is the most focused event next week for early stage companies and investors. We’ll look forward to seeing you all face to face next week.

Tags: , ,

Over 400 Qualified Life Science Investors Registered For Redefining Early Stage Investments (RESI) Conference at JP Morgan, Jan 9th at Marine Memorial Hotel, Union Square

28 Dec

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

RESI is different, in that, the LSN research team actually qualifies all the investors that attend the RESI conference. The LSN researchers, through one-on-one phone conversations, validate that all the investors have current or future mandates to invest in early stage technology assets across the domains of drugs, devices, diagnostics or healthcare IT. Fundraising CEOs and scientist entrepreneur’s don’t have to guess who they are meeting with on the other side of the table. As a matter of fact, we kindly ask the I-banks, broker dealers and debt providers to sign up as service providers so the fundraisers know who’s who in the whirlwind of meetings taking place at RESI. This will be our fourth RESI @ JPM and we expect to close down registrations due to the capacity constraint on the Marine Memorial Hotel in Union Sq. The good news is we are still accepting registrations “click here to register”.

RESI @ JPM will be the most compelling event LSN has held because the investor to fundraiser ratio will be 1-to-1, as amazing as that sounds. If you are a fundraising executive please take advantage of this opportunity to meet investors that are a fit for your stage of development and product set. RESI Partnering is now up and running with half of the meetings now booked. There is still time to dramatically impact the number of investors on your radar screen. Raising money is a numbers game, and RESI was created to help identify investors that are a fit, create a dialogue, and foster relationships that help you move towards allocations. Please scroll down and see the investors currently signed up for RESI at JPM.

Tags: , ,

Big Pharma Firms Head Upstream For New Pipeline Assets – Learn Their Strategies at RESI

21 Dec

By Lucy Parkinson, Director of Research, LSN

Major pharma firms are increasingly looking to startups to supply new assets for their pipelines, and LSN’s research has found that many are interested in inking deals at the earliest stages of drug development. Going into 2017, we found that a plurality of pharma deals announced in the previous year concerned preclinical assets.

Due to RESI’s focus on early stage life science companies, the vent has become known as a venue for top pharma firms to uncover new therapeutic opportunities. At RESI San Francisco, the panel on Big Pharma will provide an opportunity to hear straight from five experienced scouts on what they’re looking for, how they make deals and what makes a pharma partnership work.

Moderated by Chris Haskell, VP, Head of West Coast Innovation Center, Bayer Healthcare, the panelists are:

  • Kevin Lynch, Vice President, Search & Evaluation, AbbVie
  • Chris Sheldon, Head, Oncology Search & Evaluation, AstraZeneca
  • Lesley Stolz, Head, JLABS California, Johnson & Johnson Innovation
  • Chris DeRespino, Director Transactions, Amgen

Tags: ,

Orphan Drug Investors Discuss the Current Rare Disease Environment during RESI@JPM

21 Dec

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

A large number of early stage biotechs are pursuing orphan disease indications.  This trend is driven by the large number of rare diseases with either no current treatment options or severely inadequate therapies as well as the unique regulatory/development advantages available for these therapeutics. However, orphan drugs also face some unique challenges, such as clinical trial recruitment, pricing, and small market sizes. Recent developments in the space should make for an interesting year to come with the new FDA head, Dr. Scott Gottlieb, planning to eliminate the backlog of orphan drug designation requests and the halving of the orphan drug tax credit.

In the highly anticipated RESI @ JPM conference on January 9, 2018, a varied group of investors active in the orphan/rare disease space will discuss the financing and business development environment for startups working on developing drugs for orphan indications.

Moderated by Ken Kengatharan, General Partner, Atheneos Capital panelists include:

Tags: , , , ,

← Older Entries
Newer Entries →